Immunovant 

Yahoo Finance • 23 days ago

Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million?

Key Points Roivant Sciences Ltd. acquired 16,666,666 shares in a single open-market purchase on Dec. 12, 2025, for a transaction value of ~$350.0 million at $21.00 per share. The trade increased direct holdings by 17.24%, bringing Roivant... Full story

Yahoo Finance • 30 days ago

Immunovant drops 7%, prices $550M stock offering

* Clinical-stage immunology company Immunovant (IMVT [https://seekingalpha.com/symbol/IMVT]) priced [https://seekingalpha.com/pr/20336158-immunovant-announces-pricing-of-550-million-common-stock-financing] an underwritten offering of its... Full story

Yahoo Finance • last month

Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings

Immunovant, Inc. (NASDAQ:IMVT) ranks among the best short squeeze stocks to buy right now. Following the company’s fiscal second-quarter 2026 financial results, Oppenheimer reaffirmed its Outperform rating on Immunovant, Inc. (NASDAQ:IMVT)... Full story

Yahoo Finance • 2 months ago

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

Roivant Sciences BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update. B... Full story

Yahoo Finance • 2 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Immunovant Inc. Study in uncontrolled Graves’ disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment data IMVT-1402 development is progressing with potentially regi... Full story

Yahoo Finance • 2 months ago

Immunovant Q2 2026 Earnings Preview

* Immunovant (IMVT [https://seekingalpha.com/symbol/IMVT]) is scheduled to announce Q2 earnings results on Friday, November 7th, after market close. * The consensus EPS Estimate is -$0.73 [https://seekingalpha.com/symbol/IMVT/earnings/... Full story

Yahoo Finance • 2 months ago

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, Nov... Full story

Yahoo Finance • 3 months ago

Top Buys by Directors: Manheimer's $100.4K Bet on NTST

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earne... Full story

Yahoo Finance • 4 months ago

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

NEW YORK and NEW ORLEANS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The law firm of Kahn Swick & Foti, LLC (“KSF”) has commenced an investigation into Immunovant, Inc. (NasdaqGS: IMVT) (“Immunovant”). KSF is investigating whether Immunovant’s o... Full story

Yahoo Finance • 4 months ago

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3... Full story

Yahoo Finance • 4 months ago

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3... Full story

Yahoo Finance • 5 months ago

Immunovant GAAP EPS of -$0.71

* Immunovant press release [https://seekingalpha.com/pr/20195717-immunovant-provides-corporate-updates-and-reports-financial-results-for-the-quarter-ended] (NASDAQ:IMVT [https://seekingalpha.com/symbol/IMVT]): Q1 GAAP EPS of -$0.71 misse... Full story

Yahoo Finance • 5 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

Initiated a second potentially registrational study of IMVT-1402 in Graves’ disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren’s disease (SjD), both in June 2025All other clinical trials in previously announced six... Full story

Yahoo Finance • 5 months ago

OmniAb Q2 2025 slides: Partner growth accelerates despite revenue decline

OmniAb Inc. (NASDAQ:OABI) presented its second-quarter 2025 financial results and business update on August 6, revealing a company experiencing robust partner and program growth despite financial challenges. The antibody discovery platform... Full story

Yahoo Finance • 6 months ago

Immunovant (IMVT) chief technology officer Stout sells $26k in stock

Immunovant, Inc. (NASDAQ:IMVT) Chief Technology Officer Jay S. Stout, sold 1,519 shares of common stock on July 9, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average p... Full story

Yahoo Finance • 6 months ago

Goldman Sachs resumes Immunovant stock coverage with Neutral rating

Investing.com - Goldman Sachs resumed coverage of Immunovant (NASDAQ:IMVT) with a Neutral rating and set an $18.00 price target, close to InvestingPro’s Fair Value calculation. The company, currently valued at nearly $3 billion, trades wit... Full story

Yahoo Finance • 7 months ago

Roivant Sciences' president Venker sells $1.15 million in shares

Eric Venker, President and COO of Roivant Sciences (NASDAQ:ROIV), sold 100,000 common shares of the company on June 20, 2025, for $11.45 each, totaling $1.15 million. The transaction occurred near the stock’s current trading price of $11.5... Full story

Yahoo Finance • 7 months ago

Immunovant GAAP EPS of -$0.64 beats by $0.06

* Immunovant press release [https://seekingalpha.com/pr/20119506-immunovant-provides-corporate-updates-and-reports-financial-results-for-the-fourth-quarter] (NASDAQ:IMVT [https://seekingalpha.com/symbol/IMVT]): Q4 GAAP EPS of -$0.64 beat... Full story

Yahoo Finance • 9 months ago

Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?

We recently published a list of 10 Best Low Cost Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against other best low cost stocks to buy according to bi... Full story

Yahoo Finance • 10 months ago

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm... Full story